https://www.thebodypro.com/category/hiv-treatment-strategies

HIV Treatment Strategies

The Latest

triptych of medical scientists performing lab and research duties
Features

Top 10 HIV Clinical Developments of 2020

In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.

By David Alain Wohl, M.D.
scientists analyzing
Features

Fostemsavir, at Last: A New Treatment Option for Extensive HIV Drug Resistance

Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.

By David Alain Wohl, M.D.
weight gain
Features

Why Is Weight Gain Occurring Among Some People Who Start HIV Treatment?

Given the differences we’ve seen among disparate subgroups, it is highly likely that there are genetic influences on the amount of weight people gain on certain HIV therapies, argues David Wohl, M.D.

By David Alain Wohl, M.D.
complicated knot
News

This Week in HIV Research: Untangling Knots of Comorbidities

Nov. 19, 2020: Metformin's effect on weight and gut microbiota; integrase and cardiometabolics in women with HIV; ongoing link between HIV, smoking, and cancer; how early HIV treatment initiation impacts future cervical cancer outcomes.

By Barbara Jungwirth and Myles Helfand
human touch
News

This Week in HIV Research: The Human Touch

Nov. 5, 2020: Success of direct referrals at re-linking people to HIV care; stable housing = viral suppression; modern-day rates of virologic failure; how pharmacy type affects HIV treatment outcomes.

By Barbara Jungwirth and Myles Helfand
maze
News

This Week in HIV Research: A Metabolic Maze

Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.

By Barbara Jungwirth and Myles Helfand
injection
Conference Coverage

Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions

Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.

By Larry Buhl
medical trust
Features

We Need to Talk About Racism as a Barrier to HIV Prevention and Care for Black Women

HIV infection rates among Black women in the U.S. have fallen sharply over the past decade, but look closer and the numbers still paint a troubling story.

By Ginger Skinner
scale and tape measure
Conference Coverage

Flurry of New Research Explores Weight Gain on Integrase Inhibitors Among People Living With HIV

Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.

By Michael Broder
medical scale
Conference Coverage

More Research Points to Weight Increases on TAF-Containing HIV Treatment

Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.

By Michael Broder